Previous 10 | Next 10 |
Antares Pharma (NASDAQ: ATRS ) : Q2 GAAP EPS of $0.01 beats by $0.01 . More news on: Antares Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 ...
Antares Pharma (NASDAQ: ATRS ) has entered into an exclusive distribution agreement with Lunatus Global Medical Supplies to distribute and promote the sale of Xyosted in Saudi Arabia and the United Arab Emirates (UAE). More news on: Antares Pharma, Inc., Healthcare stocks ne...
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies (“Lunatus”) to distribute and promote the sa...
EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020. Managem...
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in Europe. Antares ...
EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position of Senior Vice President of Commercial. Mr. Shea will be res...
Antares Pharma ( ATRS ) is a long-term position for me, and I continue to believe the company is substantially undervalued due to its strong injector technology platform and increasing sales. In my view, the stock is largely de-risked, yet has good upside potential here. While Antares has rall...
EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9...
Antares Pharma (NASDAQ: ATRS) is one of the fastest-growing biotech stocks in the sector, with multiple collaboration agreements with large-cap pharmaceutical companies to supply it with pressure-assisted injector devices. The wheel of fortune, however, has not been kind to Antares, as its ...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...